Ausgabe Sonderheft 1/2020
Dotinurad: Novel URAT1 inhibitor
Inhalt (13 Artikel)
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
Satoru Kuriyama
Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects
Hiroshi Nakatani, Masahiko Fushimi, Tomomitsu Sasaki, Daisuke Okui, Tetsuo Ohashi
Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
Hiroyuki Fukase, Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi, Tatsuo Hosoya
Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
Yuji Kumagai, Masashi Sakaki, Kenichi Furihata, Takayoshi Ito, Kazuaki Inoue, Takafumi Yoshida, Shigeki Matsumoto, Kazuki Furuno, Atsushi Hagino
A drug–drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males
Kenichi Furihata, Katsuaki Nagasawa, Atsushi Hagino, Yuji Kumagai
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
Tatsuo Hosoya, Takafumi Sano, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
Tatsuo Hosoya, Kazuki Furuno, Shingo Kanda
Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
Tatsuo Hosoya, Masahiko Fushimi, Daisuke Okui, Tomomitsu Sasaki, Tetsuo Ohashi
The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi
A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
Tatsuo Hosoya, Kazuki Furuno, Shingo Kanda